Alzheimer's Disease

“We're at an important time for dementia. This is a time bomb. This is a terrible condition. We need to be doing more about this than in the past. Never has the health service and social care system been so fragile as it is today.” - Dame Gill Morgan NHS Providers (Chair)

Dementia, of which Alzheimer’s disease is the primary manifestation, is one of the most common and serious disorders faced by an increasingly aging population. It causes irreversible decline in global intellectual and physical functioning, progressive decline in memory, reasoning, communication skills and the ability to carry out daily activities as well as behavioural and psychological symptoms.

This also has profound, negative effects on family members. Family carers are often old and frail themselves and have high levels of carer burden, depression and physical illness.

Incidence and Prevalence

  • Dementia is a global issue. The current best estimate is that dementia currently affects 35.6 million people worldwide, 0.5% of the global population
  • The estimated number of people with dementia will double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050.
  • There are 7.7 million new cases of dementia each year, implying that there is a new case of dementia somewhere in the world every four seconds.
  • An estimated 5.2 million Americans have Alzheimer's disease in 2014. 1 in 3 U.S. senior citizens die with dementia.
  • In the UK, dementia affects 800,000 people with 200,000 new cases a year

The Economic Impact

  • In the 2010 World Alzheimer Report (ADI, 2010), the global annual economic impact of dementia was estimated to be $604 billion.
  • If dementia were a business, it would be the world’s largest company by turnover - bigger than Wal-Mart and Exxon Mobil.
  • If dementia were a country it would be the world’s 18th largest economy.
  • In response to this increasing understanding of the strategic importance of dealing with dementia effectively, dementia has been made a national and international health and social care priority with the development of the National Dementia Strategy, the Prime Minister’s Challenge and the 2013 G8 Summit on dementia (DH et al, 2013).

UK Economic Effects

  • Dementia costs over £20 billion per year in the UK, more than stroke, heart disease and cancer put together.
  • In 30 years the numbers will double to over one and a half million and the costs will rise at least three-fold to over £50 billion.

The Market

The Pharmaceutical Industry’s revenues for 2013 reached $950 billion and are expected to surpass $1.2 trillion by the end of 2016. But in the under-served area of dementia, even though the number of patients being diagnosed is rising dramatically, the lack of any effective treatment means that the global market for Alzheimer's disease, which reached $10.2 billion in 2012, is expected to decrease at a compound annual growth rate of -1.5% to reach $9.5 billion in 2017 unless a safe and effective new treatment can be discovered and authorised.

The potential

The exponential rise in the number of patients presenting with Alzheimer's disease in the coming years, represents a significant market opportunity for therapeutics.

A novel, effective Alzheimer’s therapeutic product such as AIMSPRO, once regulated, could become one of the treatment options for patients suffering with this debilitating disease.